NAD+ & longevity
Research and coverage from the field — the useful, the early, and the overstated. Every item links to its source. None of it is about AgeleX.
Randomised, double-blind, placebo-controlled · n=140 · healthy overweight adults 40–60 · Conze D, Brenner C, Kruger CL
The dose-response trial the 500 mg serving in AgeleX sits inside. It measured NAD+ in blood, not health outcomes.
Read the source →Randomised, double-blind, placebo-controlled crossover · Martens CR, et al.
Worth reading precisely because the headline finding is a null one. This is where the category's promises tend to get ahead of the data.
Read the source →Older men · muscle biopsies · Elhassan YS, et al.
Tissue-level rather than blood-level — a harder measurement, and a narrower population.
Read the source →Human tissue samples · Massudi H, et al.
The measurement the whole category is built on — and the one most often quoted without its bounds.
Read the source →Everything on this page is about NAD+ and its precursors as a field. None of these researchers or publications has any relationship with AgeleX, and nothing here is an endorsement of any product.‡
Media enquiries — press@agelex.us
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
† Individual results may vary.
‡ Cited results describe studied ingredients, not the finished AgeleX product.